Medy-Tox Inc - Asset Resilience Ratio

Latest as of September 2025: 0.04%

Medy-Tox Inc (086900) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Medy-Tox Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩252.96 Million

≈ $171.43K USD Cash + Short-term Investments

Total Assets

₩586.91 Billion

≈ $397.74 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how Medy-Tox Inc's Asset Resilience Ratio has changed over time. See Medy-Tox Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Medy-Tox Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medy-Tox Inc stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩252.96 Million	0.04%
Total Liquid Assets	₩252.96 Million	0.04%

Asset Resilience Insights

Limited Liquidity: Medy-Tox Inc maintains only 0.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Medy-Tox Inc Industry Peers by Asset Resilience Ratio

Compare Medy-Tox Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Medy-Tox Inc (2013–2024)

The table below shows the annual Asset Resilience Ratio data for Medy-Tox Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.59%	₩59.00 Billion ≈ $39.98 Million	₩615.16 Billion ≈ $416.89 Million	+4.15pp
2023-12-31	5.44%	₩33.27 Billion ≈ $22.55 Million	₩611.62 Billion ≈ $414.49 Million	+1.05pp
2022-12-31	4.39%	₩26.19 Billion ≈ $17.75 Million	₩596.29 Billion ≈ $404.10 Million	-9.79pp
2021-12-31	14.18%	₩81.92 Billion ≈ $55.52 Million	₩577.70 Billion ≈ $391.50 Million	+2.29pp
2020-12-31	11.89%	₩55.61 Billion ≈ $37.68 Million	₩467.76 Billion ≈ $317.00 Million	+6.31pp
2019-12-31	5.58%	₩23.51 Billion ≈ $15.93 Million	₩421.53 Billion ≈ $285.66 Million	-0.85pp
2018-12-31	6.42%	₩25.38 Billion ≈ $17.20 Million	₩395.01 Billion ≈ $267.70 Million	-2.33pp
2017-12-31	8.76%	₩33.36 Billion ≈ $22.61 Million	₩380.95 Billion ≈ $258.16 Million	-0.66pp
2016-12-31	9.42%	₩30.53 Billion ≈ $20.69 Million	₩324.03 Billion ≈ $219.59 Million	-15.03pp
2015-12-31	24.45%	₩49.77 Billion ≈ $33.73 Million	₩203.55 Billion ≈ $137.94 Million	-22.76pp
2014-12-31	47.21%	₩79.55 Billion ≈ $53.91 Million	₩168.51 Billion ≈ $114.20 Million	+29.21pp
2013-12-31	18.00%	₩14.30 Billion ≈ $9.69 Million	₩79.41 Billion ≈ $53.82 Million	--

pp = percentage points

About Medy-Tox Inc

KQ:086900 Korea Biotechnology

Market Cap

$374.05 Million

₩551.96 Billion KRW

Market Cap Rank

#13867 Global

#427 in Korea

Share Price

₩83900.00

Change (1 day)

-4.00%

52-Week Range

₩77700.00 - ₩177900.00

All Time High

₩671543.08